Biosimilar Market Size Worth US$ 20.2 Billion by 2024 | CAGR 33%%

1. Global Biosimilar Market Research Report and Forecast 2024 Report Edition: 2019 Copyright © IMARC Service Pvt Ltd. All Rights Reserved © 2019 IMARC All Rights Reserved

2. Report DescriptionAbout IMARC Group The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value challenges, and transform their businesses. opportunities, address their most critical IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

3. Report Description and Highlights Report Description Global Biosimilar Market Overview: According to the recent report by IMARC Group, entitled “Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, the global biosimilar market size was estimated to be US$ 3.8 Billion in 2018. Biosimilars, also known as subsequent entry biologics (SEBs) or follow-on biologics, refer to FDA-approved biotherapeutic products which are similar to their reference biologics. Biosimilars can only be manufactured after the patent of the reference product expires. The demand for biosimilars has been increasing in recent years as they help in reducing the overall cost of the treatment for a variety of chronic diseases including cancers, autoimmune diseases, kidney failure, diabetes, CVDs, haematological disorders, infectious diseases, rheumatoid arthritis, growth hormone deficiency, etc. Global Biosimilar Market Trends Recent patent expiries of a large number of blockbuster biological drugs such as Humira, Remicade, MabThera, Enbrel, etc. have majorly boosted the growth of the biosimilar market. Another major growth-inducing factor is ageing population which has led to a rise in the prevalence of non- communicable diseases.

4. Report Description and Highlights Report Description 186.5 181.2 120.2125.5130.8136.1141.4146.7152.0157.3 175.9 170.6 160 180 165.3 160.0 160 140 140 120 In Billion US$ in Billion US$ 120 100 100 80 80 60 60 40 40 20 20 0 0 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 This has resulted into the low cost of these drugs in comparison to their branded counterparts, in turn, spurring their demand worldwide. Due to the abovementioned factors, the market is projected to expand at a CAGR of nearly 33% during 2019-2024, registering a value of US$ 20.2 Billion by 2024. Request for a free sample report: https://www.imarcgroup.com/biosimilar-market/requestsample

5. Report Description and Highlights Report Description Further, high costs of innovator biologics, especially monoclonal antibodies (mAbs), have encouraged several governments across the globe to promote the usage of biosimilars. For instance, European countries like the Netherlands, Denmark and Germany have established strategic models for discount pricing and introduced numerous incentive programs. Apart from this, biosimilars do not require extensive marketing as the safety and efficacy profile of biologics has already been established. Key Market Segmentation: Market Segmentation by Type of Manufacturing • • In-house Manufacturing Contract Manufacturing On the basis of type of manufacturing, the market has been bifurcated into in-house and contract manufacturing. Currently, in-house manufacturing holds around three-fourth of the total share, representing the dominant segment. This method enables the manufacturers to monitor every step of the biosimilars’ production process and eliminates both shipping and delivery costs. For more information, click here: https://www.imarcgroup.com/biosimilar-market

6. Report Description and Highlights Report Description Market Segmentation by Molecule Type • • • • • • • • Infliximab Insulin Glargine Epoetin Alfa Etanercept Filgrastim Somatropin Rituximab Follitropin Alfa Based on molecule type, Infliximab represents the largest segment, accounting for the majority of the total market share. Other major categories include Insulin Glargine, Epoetin Alpha, Ethanercept, Filgrastim, Somatropin, Rituximab and Follitropian Alfa. Market Segmentation by Indication • Auto-Immune Diseases

7. Report Description and Highlights Report Description • • • • • Blood Disorder Diabetes Oncology Growth Deficiency Female Infertility The market has also been segregated on the basis of indication as autoimmune diseases, oncology, diabetes, blood disorder, growth deficiency and female infertility. Amongst these, autoimmune diseases account for around a half of the global share. Market Segmentation by Region • Europe o Italy o Germany o France o United Kingdom o Spain

8. Report Description and Highlights Report Description o Rest of Europe United States Japan India South Korea Rest of the World • • • • • Region-wise, Europe is the leading market with more than a half of the global share. This can be attributed to the large ageing population in the region. Besides Europe, other major regions include the United States, India, Japan and South Korea. Competitive Landscape: The competitive landscape of the market has also been examined with some of the key players. • • • Novartis Pfizer Teva

9. Report Description and Highlights Report Description • • • • • • • • Celltrion Merck & Co Samsung Bioepis Eli Lilly Biocon Amgen Dr. Reddy's Laboratories Boehringer Ingelheim Browse Related Report Biosimilar Market In Europe: https://www.imarcgroup.com/europe-biosimilar-market Oncology Biosimilar Market Report: https://www.imarcgroup.com/oncology-biosimilars-market

10. We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients

11. We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients

12. Report Description and Highlights Report Description © 2019 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

13. Contact Us FOR MORE DETAILS Visit us at : https://www.imarcgroup.com Stay With Us: TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com